Chapman Financial Group LLC bought a new stake in Bruker Co. (NASDAQ:BRKR - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 8,047 shares of the medical research company's stock, valued at approximately $472,000.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Eagle Bay Advisors LLC grew its holdings in Bruker by 2,324.1% during the fourth quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company's stock worth $41,000 after buying an additional 674 shares in the last quarter. UMB Bank n.a. grew its position in shares of Bruker by 37.5% during the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock valued at $53,000 after acquiring an additional 248 shares during the period. GAMMA Investing LLC grew its position in shares of Bruker by 47.5% during the 4th quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock valued at $75,000 after acquiring an additional 412 shares during the period. Quadrant Capital Group LLC increased its stake in shares of Bruker by 18.2% during the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock worth $75,000 after purchasing an additional 196 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Bruker by 41.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,330 shares of the medical research company's stock worth $78,000 after purchasing an additional 390 shares during the period. 79.52% of the stock is owned by institutional investors.
Bruker Trading Down 0.7 %
Shares of BRKR traded down $0.28 during mid-day trading on Thursday, reaching $40.48. The company's stock had a trading volume of 4,926,588 shares, compared to its average volume of 1,551,963. The stock has a market cap of $6.13 billion, a PE ratio of 53.26, a P/E/G ratio of 2.16 and a beta of 1.23. The company's fifty day moving average price is $41.43 and its two-hundred day moving average price is $51.37. Bruker Co. has a 52 week low of $34.10 and a 52 week high of $79.78. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15.
Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.01. The business had revenue of $801.40 million during the quarter, compared to analysts' expectations of $763.83 million. Bruker had a return on equity of 21.01% and a net margin of 3.36%. The business's revenue was up 11.0% on a year-over-year basis. During the same quarter last year, the business posted $0.53 EPS. On average, analysts predict that Bruker Co. will post 2.69 earnings per share for the current fiscal year.
Bruker Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were issued a $0.05 dividend. The ex-dividend date was Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a yield of 0.49%. Bruker's dividend payout ratio (DPR) is 26.32%.
Analyst Ratings Changes
BRKR has been the topic of a number of recent research reports. UBS Group dropped their price target on Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday. The Goldman Sachs Group reduced their target price on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating for the company in a research note on Thursday. Citigroup cut their price objective on shares of Bruker from $75.00 to $50.00 and set a "buy" rating for the company in a report on Monday, April 7th. Barclays lowered their target price on shares of Bruker from $50.00 to $46.00 and set an "overweight" rating on the stock in a report on Thursday. Finally, Guggenheim reiterated a "buy" rating on shares of Bruker in a research report on Monday, February 24th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $60.10.
View Our Latest Stock Analysis on BRKR
About Bruker
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Further Reading
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
